ADAM12 was also regarded as a new biomarker of ovarian cancer, because of its low expression levels in normal tissues and high expression levels in ovarian cancer tissues, and high expression levels were associated with a poor survival in aggressive ovarian cancer as well [30, 31]. This evidence concerns the gene ADAM12 and ovarian cancer.